MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated activity ac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology Jg. 38; H. 32; S. 3753
Hauptverfasser: Monk, Bradley J, Grisham, Rachel N, Banerjee, Susana, Kalbacher, Elsa, Mirza, Mansoor Raza, Romero, Ignacio, Vuylsteke, Peter, Coleman, Robert L, Hilpert, Felix, Oza, Amit M, Westermann, Anneke, Oehler, Martin K, Pignata, Sandro, Aghajanian, Carol, Colombo, Nicoletta, Drill, Esther, Cibula, David, Moore, Kathleen N, Christy-Bittel, Janna, Del Campo, Josep M, Berger, Regina, Marth, Christian, Sehouli, Jalid, O'Malley, David M, Churruca, Cristina, Boyd, Adam P, Kristensen, Gunnar, Clamp, Andrew, Ray-Coquard, Isabelle, Vergote, Ignace
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 10.11.2020
Schlagworte:
ISSN:1527-7755, 1527-7755
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!